SARC032 Expanded

SU2C has made additional funds available for SARC032 so that we can increase the sample size and power of this randomized, ongoing trial from 102 to 126 evaluable patients. SARC032 …

Read more

Now Recruiting:  CHIEF MEDICAL OFFICER

SARC is seeking a part-time Chief Medical Officer (CMO). The CMO (a newly created role for SARC) will work in partnership with the Chief Executive Officer (CEO) and Chief Scientific …

Read more

SARC 2022 Career Development Award

SARC is pleased to announce our 2022 Career Development Award (CDA) funding opportunity. Past graduates (link here) of the SARC CDA program are pursuing productive independent careers at leading institutions …

Read more

SARC024

Texas Children’s Cancer and Hematology Centers is now open to enrollment in SARC024 (Regorafenib/Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas). SARC024 sites include: • Atrium Health Levine Cancer Institute (Atlanta, GA)• …

Read more
Jonathan Fletcher

SARC appoints Chief Scientific Officer

SARC is pleased to announce that Dr. Jonathan Fletcher has been appointed Chief Scientific Officer. Dr. Fletcher is a lab-based medical and pediatric oncologist at Harvard Medical School, Brigham and Women’s …

Read more

July is Sarcoma Awareness Month

SARC collaborator SFA is hosting a virtual Advocacy Day on July 21, 2021, during Sarcoma Awareness Month. If you would like to be a part of this day, or to learn …

Read more

JUNE 4, 2021 SARC SEMIANNUAL MEETING

Thank you for attending the 2021 SARC Semiannual Virtual Meeting on June 4, 2021. If you were not able to join the virtual event please view the agenda along with …

Read more